Outset Medical, Inc. (NASDAQ:OM – Get Rating) CTO Jean-Olivier Racine sold 1,157 shares of the firm’s stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $14.50, for a total value of $16,776.50. Following the completion of the sale, the chief technology officer now owns 40,920 shares of the company’s stock, valued at $593,340. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NASDAQ:OM opened at $16.30 on Monday. Outset Medical, Inc. has a twelve month low of $13.25 and a twelve month high of $60.33. The company has a market cap of $779.04 million, a price-to-earnings ratio of -5.51 and a beta of 2.13. The stock has a fifty day simple moving average of $25.78 and a 200-day simple moving average of $36.12. The company has a current ratio of 7.72, a quick ratio of 6.84 and a debt-to-equity ratio of 0.09.
Outset Medical (NASDAQ:OM – Get Rating) last announced its quarterly earnings results on Wednesday, May 4th. The company reported ($0.78) EPS for the quarter, meeting the consensus estimate of ($0.78). The firm had revenue of $30.55 million for the quarter, compared to analyst estimates of $30.35 million. Outset Medical had a negative return on equity of 35.58% and a negative net margin of 125.91%. As a group, equities research analysts predict that Outset Medical, Inc. will post -2.72 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. Advisor Group Holdings Inc. increased its stake in shares of Outset Medical by 253.6% during the fourth quarter. Advisor Group Holdings Inc. now owns 1,326 shares of the company’s stock valued at $61,000 after buying an additional 951 shares during the period. Fieldpoint Private Securities LLC purchased a new position in Outset Medical in the fourth quarter valued at about $67,000. IFP Advisors Inc purchased a new position in Outset Medical in the fourth quarter valued at about $82,000. US Bancorp DE grew its stake in Outset Medical by 286.7% in the first quarter. US Bancorp DE now owns 2,711 shares of the company’s stock valued at $123,000 after purchasing an additional 2,010 shares during the last quarter. Finally, Crossmark Global Holdings Inc. purchased a new position in Outset Medical in the fourth quarter valued at about $216,000.
OM has been the subject of a number of analyst reports. Cowen lowered their price target on Outset Medical from $60.00 to $33.00 and set an “outperform” rating for the company in a research report on Tuesday, June 14th. Cowen decreased their target price on Outset Medical from $60.00 to $33.00 in a research report on Tuesday, June 14th. Stifel Nicolaus decreased their target price on Outset Medical from $55.00 to $30.00 in a research report on Tuesday, June 14th. Finally, Bank of America assumed coverage on Outset Medical in a research report on Wednesday, March 2nd. They set a “buy” rating for the company.
Outset Medical Company Profile (Get Rating)
Outset Medical, Inc, a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.
See Also
Receive News & Ratings for Outset Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Outset Medical and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
